Tone mix
Week by week 52 weeks
Share of Alnylam Pharmaceuticals, Inc.'s 255 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Dec 22, 2025 · tone +98Here's Why Alnylam Pharmaceuticals (ALNY) Surged in Q3+87
- Week of Dec 29, 2025 · tone +99Alnylam Pharmaceuticals Expands Norton, Massachusetts, Research Operations+81
- Week of Aug 31, 2026 · tone +78Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at HC Wainwright+71
- Week of Apr 20, 2026 · tone -59Truist Lowers PT on Alnylam Pharmaceuticals (ALNY) to $505 From $515-69
- Week of Mar 30, 2026 · tone +66Why Alnylam Pharmaceuticals Inc. (ALNY) is One of the Best High Growth Healthcare Stocks to Buy Now+49
- Week of Sep 21, 2026 · tone +49Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at HC Wainwright+46
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Alnylam Pharmaceuticals, Inc. in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 5 | -2 |
| Last 30 sessions | 19 | -11 |
| Last 90 sessions | 77 | +5 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, November 5, 2026
1 headline, average tone -100: 0 positive, 0 neutral and 1 negative. Showing all 1.
- www.tickerreport.com · 1 outletAlnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from BarclaysNegative
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Barclays | www.tickerreport.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Monday, November 2, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outlet5,421 Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by ProShare Advisors LLCNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| 5,421 Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by ProShare Advisors LLC | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 30, 2026
2 headlines, average tone +44: 1 positive, 1 neutral and 0 negative. Showing all 2.
- www.fool.com · 2 outletsAlnylam (ALNY) Q3 2026 Earnings Call TranscriptNeutral
- www.rttnews.com · 1 outletAlnylam Pharmaceuticals Shares Update About Phase 3 Nucresiran Study, Reaffirms FY26 OutlookPositive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Alnylam (ALNY) Q3 2026 Earnings Call Transcript | www.fool.com | 2 | Neutral |
| Alnylam Pharmaceuticals Shares Update About Phase 3 Nucresiran Study, Reaffirms FY26 Outlook | www.rttnews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 29, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- 247wallst.com · 1 outletAlnylam Pharmaceuticals (ALNY) Stock Price, News & AnalysisNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis | 247wallst.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.finanznachrichten.de · 1 outletAlnylam Pharmaceuticals, Inc.: Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's DiseasePositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Alnylam Pharmaceuticals, Inc.: Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease | www.finanznachrichten.de | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Alnylam Pharmaceuticals, Inc., not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.